Recruiting
The Effect of Aerobic and Resistance Training in Patients With Type 2 Diabetes on Vitamin D Treatment
The purpose of this study protocol is to assess the effect of concurrent aerobic and resistance training in patients with type 2 diabetes on vitamin D treatment
ClinicalTrials.gov IDNCT06081387
PhaseNA
Enrollment80
SponsorUniversity Ramon Llull
Age40 Years
SexALL
Conditions studied
Diabetes Mellitus, Type 2
About this study
The purpose of this study protocol is to assess the effect of concurrent aerobic and resistance training in patients with type 2 diabetes on vitamin D treatment
Interventions
- Other: Resistance training — Sarcoplasm stimulating training system. This program will run for a total of 16 weeks and three sessions a week. This exercise plan is designed in three 5-week periods plus a familiarization session.
Primary outcomes
- Change in Homeostatic Model Assessment of Insulin Resistance (HOMA IR) (Beginning of the study and after 4 months)
- Change in Homeostasis model assessment of β-cell function (HOMA-β) (Beginning of the study and after 4 months)
- Change in serum levels of Hemoglobin A1c. (Beginning of the study and after 4 months)
- Change in serum lipid profile (Beginning of the study and after 4 months)
- Change in weight (Beginning of the study and after 4 months)
- Change in waist circumference (Beginning of the study and after 4 months)
- Change in Body Mass Index (BMI) (Beginning of the study and after 4 months)
- Vitamin D (Beginning of the study)
Eligibility information
Inclusion Criteria:
* Adults (females or males) older than 18 years old with a diagnosis of T2D in the clinic database
* Patients who have been taking the combination therapy of metformin + sodium-glucose transport protein 2 inhibitors (iSGLT2), as recommended by the redGDPS 2023, with stable medication for the past 6 months.
* Diabetic patients taking prescribed VitD treatment for at least 6 months (intervention group) and diabetic patients not taking prescribed VitD (control group)
* Patients who signed the informed consent
* Patients capable of performing mild to moderate physical activity (to walk steadily and independently for at least 6 minutes)
Exclusion Criteria:
* Patients taking other medication different than metformin + iSGLT2 (including combinations and insulin)
* Patients taking polyvitaminic supplementation at the inclusion for at least, 1 month before the intervention
* Female subjects who are pregnant
* Patients who did not sign the informed consent
Study locations
- CAP Sant Rafael, Barcelona, Spain
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-28.